Instem Secures Portion of €2.5m Grant as Member of Research Consortium Investigating the Mutagenicity of N-nitrosamines
Newly Added Services to Support Latest Regulatory Guidance and Growing Demand for Alternative Testing Methods
Acquisition of PDS Life Sciences Consolidates Non-Clinical Market; Further Extends Instem’s Leadership in Study Management and Regulatory SEND Submission Support
Powerful New In Silico Models and First-to-Market Software Capabilities to Deliver Further Efficiencies and Increased Regulatory Compliance
Instem’s Acquisition of Leading Clinical Trial Technology and Consulting Provider d-wise Represents Substantial Advancement of its Mission
Instem’s Acquisition of Discovery Technology Solutions Provider, The Edge, Represents Another Advancement of its Mission in the Life Sciences
